Skip to content

Phase IV study, randomized, placebo-controlled for the evaluation of efficacy and tolerability of arginine aspartate in patients with moderate to severe fatigue

Phase IV study, randomized, placebo-controlled for the evaluation of efficacy and tolerability of arginine aspartate in patients with moderate to severe fatigue

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12608000535370
Enrollment
60
Registered
2008-10-22
Start date
2009-01-02
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Fatigue is a very frequent symptom and is present in 50% of patients that seek a doctor’s appointment. Fatigue could be defined as an oppressive feeling, sustained by exhaustion and reduced capacity of physical and mental works on the habitual level. Its defining characteristics include signs and symptoms that are linked to the control of body energy, to difficulty in doing daily normal activities, to verbalization of extreme exhaustion, and contribute to generation and establishment of lack of concentration, lack of interest, reduced libido and a feeling of guilt for not playing expected social roles. The L-arginin is a precursor in the synthesis of Nitric Oxide (NO). This Oxide is a molecule that plays different roles in the body. Among them is the stimulation of the immunological response mediated by lymphocytes and macrophages; the reduction of the blood platelet hiperaggregation and the maintenance of vascular tonus in the regulation of arterial pressure, that involves the dynamic equilibrium between NO and endothelins. The L-arginin is a semi-essential aminoacid produced by the body, although it is not an enough production for all what is needed for. The arginin aspartate can also decrease fatigue and acts in several types of asthenia, strengthening the muscular capacity and having a support role in the treatment of various processes including the ones caused by stress. In prolonged administration of arginin, there is an increase in the production of Nitric Oxide, and its supplementation has been related to an improvement of the contractile function of the skeletal muscle. The hypothesis that this improvement in muscular strength occurs in the short term has been related to the vasodilator effect of the NO with consequent improvement of muscular perfusion. If we take into consideration that fatigue is a sufficiently important symptom to compromise the quality of life, leading a person to feel limited in dealing with her daily chores since once she initiates her activities, she can feel tired prematurely; supplementation with arginin would increase the production of NO with improvement of muscular response to the daily life activities, this way, decreasing the intensity or even eliminating the symptom fatigue. The objective of this study is to find fatigue descrease by Piper Scale. The classification of the Piper scale has to decrease after 60 days of treatment comparing to basal classification (before treatment).

Interventions

Arginine aspartate 250mg administration orally during 60 days, 2 tablets twice a day (after breakfeast and after dinner)

Sponsors

Nikkho Zydus
Lead SponsorCommercial sector/Industry

Study design

Allocation
Randomised controlled trial
Primary purpose
Treatment

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

Patients between 18 to 70 years old Informed consent Rate = or more than 4 in the Piper Scale

Exclusion criteria

Pregnants Depression Organic disease

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026